Nine days after we put a tobacco sleeve into seven model books, the largest name in it poured concrete. Philip Morris International (PM) opened a $1.2 billion manufacturing campus in Aurora, Colorado, part of the company’s effort to expand its Zyn portfolio and meet rising demand for nicotine pouches. The detail that matters is not the ribbon-cutting. It is the budget line.
A project that doubled while it was being built
The Aurora plant was originally announced in 2024 as a $600 million project. It opened as a $1.2 billion one. The site began commercial production earlier this month after approximately 19 months of construction, and the roughly 780,000-square-foot campus manufactures Zyn nicotine pouches, positioning Aurora as a strategic production and export hub for future growth.
“This facility expands our production capacity, strengthens our supply chain, and enhances our ability to serve growing demand in the United States and around the world,” said Stacey Kennedy, chief executive of Philip Morris U.S. “It reflects our confidence in American workers, U.S. manufacturing, and the long-term growth opportunities ahead for our business.” Philip Morris has invested about $1 billion in the campus so far and plans to invest an additional $200 million over the next two years in the facility’s next phase of development, which will add production capacity and expand the site. The expansion is meant to support Zyn’s growth in the United States as well as opportunities in Asia, Latin America and the Caribbean. The company said last week it would ramp up investments in its U.S. business, aiming to keep Zyn the go-to nicotine pouch for Americans.
Why a building is evidence
Companies say encouraging things about product transitions in every earnings call. Very few of them double a factory’s budget in the middle of construction for a product they privately doubt. Capital expenditure is the least ambiguous disclosure a management team makes, because it is the one that cannot be revised in a footnote. A plant is a decade-long statement about expected volume.
That is the whole reason this page exists. On July 22 we bought the pouch transition rather than the cigarette — Philip Morris as the core position, British American Tobacco (BTI) where the mandate fits, and Altria (MO) in the income books, at roughly 1% to 6% weights across the dividend, income, midterm-dividend, conservative, diversified, global and scenario books, funded out of cash and short bills. Nine days later the largest holding in that sleeve spent $1.2 billion telling us the transition is real.
The sleeve thesis, and where to read it
The underlying case has not changed since we wrote it. Jeremy Siegel’s finding — that Philip Morris was the single best-performing stock in the S&P 500 from 1957 to 2003, compounding at 19.75% a year against the index’s 10.85% — is not an argument that tobacco is a good business in the abstract. It is an argument about what happens to a hated, cash-generative business whose dividends are reinvested at a permanently depressed multiple.
The full construction of the position is on two companion pages: the sleeve thesis, as we sized and funded it on July 22, and the original July 10 tobacco trade note where the argument started. Read them in that order if you want the reasoning rather than the headline.
The risk that did not move
A $1.2 billion building does not change a regulator’s mind. The category exists at the pleasure of the Food and Drug Administration, and the same agency that authorized the pouch can revisit flavors, nicotine levels or marketing at any point in the product cycle. Nothing about the Aurora campus makes that risk smaller; if anything, a bigger domestic footprint makes the company a larger target for the next rulemaking. We size the sleeve accordingly — 1% to 6%, never a concentrated bet.
Two housekeeping notes. The halal book excludes tobacco permanently and is unaffected by any of this; individual client screens are honored automatically, and no position is added to a book that has excluded the category. And a footnote for the curious: Altria turns up again later in this week’s coverage as the owner of one of America’s most generous retirement plans, contributing 13% to 17% in total. The house wins twice.
On July 22 we bought the pouch transition, not the cigarette — PM as core, British American Tobacco (BTI) where the mandate fits, Altria (MO) in the income books. The Aurora campus is management spending like the transition is real: doubling a factory’s budget mid-build is not what a company does with a product it doubts. Action: REINFORCE PM inside the existing 1–6% sleeve weights; HOLD MO and BTI. The risk has not moved: the FDA giveth and the FDA taketh away, and a $1.2 billion building does not change a regulator’s mind. Halal book still excludes tobacco permanently; client screens honored automatically.
Philip Morris (PM) · Altria (MO) · British American Tobacco (BTI)
Tickers are named to identify the businesses discussed. They are not recommendations, and a name appearing here does not mean it is held in any model.